E0 ConsensusModerate confidencePEM not requiredReview-NarrativePeer-reviewedMachine draft
The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder.
Gruber, A J, Hudson, J I, Pope, H G · The Psychiatric clinics of North America · 1996 · DOI
Quick Summary
This review examined whether antidepressant medications help treat several chronic conditions—including ME/CFS, fibromyalgia, migraines, and irritable bowel syndrome—that often occur alongside depression. The researchers found that many different types of antidepressants appeared to benefit these disorders, suggesting they might share a common underlying biological problem. However, the studies reviewed varied widely in quality and design, so stronger research is needed to confirm these findings.
Why It Matters
For ME/CFS patients, this review suggests antidepressant medications warrant investigation as potential treatments and indicates that ME/CFS may share underlying biological mechanisms with other chronic conditions. Understanding these potential connections could inform future research into ME/CFS pathophysiology and expand treatment options for patients with both ME/CFS and comorbid depression or other interface disorders.
Observed Findings
- Multiple antidepressant classes (varying chemical families) showed benefit across ME/CFS, fibromyalgia, migraine, IBS, atypical facial pain, and PMDD to varying degrees.
- Many studies found little correlation between improvement in psychological symptoms and physical symptoms within individual disorders.
- Doses of antidepressants, especially tricyclics, were often substantially lower than those used for major depressive disorder.
- Included studies used diverse designs, diagnostic criteria, and outcome measurement methods.
Inferred Conclusions
- Antidepressant agents deserve aggressive further investigation in these interface disorders using rigorous, modern study designs.
- The consistent benefit across chemically unrelated antidepressants suggests a shared etiologic mechanism rather than multiple independent drug properties.
- Antidepressant medication trials should be strongly considered in clinical practice for patients with these interface disorders.
- Other psychotropic medications may have roles in treating individual disorders within this group.
Remaining Questions
- What is the specific shared biological mechanism underlying the antidepressant-responsive interface disorders?
- Why do some studies show dissociation between physical and psychological symptom improvement?
What This Study Does Not Prove
This review does not prove that ME/CFS is primarily a psychiatric disorder or caused by depression—the authors noted weak correlations between psychological and physical symptom improvement, arguing against a simple relationship to major depression. It does not establish causation or identify the specific biological mechanism linking these disorders. The heterogeneous quality of included studies limits definitive conclusions about which antidepressants are truly effective for ME/CFS specifically.
Tags
Symptom:PainFatigue
Method Flag:Weak Case DefinitionMixed Cohort
Metadata
- DOI
- 10.1016/s0193-953x(05)70292-6
- PMID
- 8827194
- Review status
- Machine draft
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →